B of A Securities Maintains Buy on Sana Biotechnology, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Neutral 65.3%

Neg 0% Neu 65.3% Pos 0%

B of A Securities analyst Alex Stranahan maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $7 to $6.